共 50 条
Case report: Fecal microbiota transplantation in refractory ankylosing spondylitis
被引:5
作者:
Wang, Lei
[1
]
Wei, Zhimin
[2
]
Pan, Fei
[3
]
Song, Chuan
[1
]
Peng, Lihua
[3
]
Yang, Yunsheng
[3
]
Huang, Feng
[1
]
机构:
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Rheumatol & Immunol, Beijing, Peoples R China
[2] Gen Off Cent Comm Communist Party China, Hlth Serv Dept, Guard Bur, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Gastroenterol & Hepatol, Microbiota Div, Beijing, Peoples R China
来源:
FRONTIERS IN IMMUNOLOGY
|
2023年
/
14卷
关键词:
ankylosing spondylitis;
ulcerative colitis;
fecal microbiota transplantation;
gut microbiota;
case report;
METAGENOMICS REVEALS;
INTESTINAL DYSBIOSIS;
GUT MICROBIOTA;
THERAPY;
D O I:
10.3389/fimmu.2023.1093233
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Ankylosing spondylitis (AS) is the prototype of a group of systemic inflammatory diseases referred to as spondyloarthritis. Comorbid inflammatory bowel disease and changed gut microbiota in AS have attracted attention to the influence of gut-joint axis and encouraged treating AS by targeting gut microbiota. Here we first reported a patient with refractory AS and comorbid ulcerative colitis (UC) who underwent three fecal microbiota transplantations (FMTs). Inadequate response to conventional treatments including tumor necrosis factor inhibitors impelled FMT as alternative therapy. Notable improvements in AS and UC accompanied with changed fecal microbiota were recorded at 1 week post-FMT1. Further recovery was found after the other two FMTs, and a roughly stable status was maintained in the follow-up period. More studies are needed to validate the effectiveness of FMT in AS and its mechanisms.
引用
收藏
页数:6
相关论文
共 50 条